This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Fiebrich, H.-B. Articles by Links, T. P. PubMed PubMed Citation Articles by Fiebrich, H.-B. Articles by Links, T. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Adrenal Gland Cancer CT Scans MRI Scans Nuclear Scans Pheochromocytoma Related Collections Adrenal and Hypertension Cardiovascular Endocrinology Endocrine Oncology

6-[F-18]Fluoro-L-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with ¹²³I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess

Departments of Medical Oncology (H.-B.F., E.G.E.d.V.), Nuclear Medicine and Molecular Imaging (A.H.B., J.R.d.J., P.H.E., R.A.J.O.D.), Endocrinology (M.N.K., W.J.S., T.P.L.), Laboratory Medicine (I.P.K.), and Pathology (J.E.v.d.W.), University Medical Center Groningen, 9700 RB Groningen and Department of Radiology (M.E.J.P.), Martini Hospital, 9728 NT Groningen, The Netherlands; and Department of Nuclear Medicine (P.L.J.), Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada L8N 3Z5

Address all correspondence and requests for reprints to: T. P. Links, M.D., Ph.D., Department of Endocrinology, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands. E-mail: t.p.links{at}int.umcg.nl.

Context: Catecholamine excess is rare, but symptoms may be life threatening.

Objective: The objective of the study was to investigate the sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography (¹⁸F-DOPA PET), compared with ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy and computer tomography (CT)/magnetic resonance imaging (MRI) for tumor localization in patients with catecholamine excess.

Design and Setting: All consecutive patients with catecholamine excess visiting the University Medical Center Groningen, Groningen, The Netherlands, between March 2003 and January 2008 were eligible.

Patients: Forty-eight patients were included. The final diagnosis was pheochromocytoma in 40, adrenal hyperplasia in two, paraganglioma in two, ganglioneuroma in one, and unknown in three.

Main Outcome Measures: Sensitivities and discordancy between ¹⁸F-DOPA PET, ¹²³I-MIBG, and CT or MRI were analyzed for individual patients and lesions. Metanephrines and 3-methoxytyramine in plasma and urine and uptake of ¹⁸F-DOPA with PET were measured to determine the whole-body metabolic burden and correlated with biochemical tumor activity. The gold standard was a composite reference standard.

Results: ¹⁸F-DOPA PET showed lesions in 43 patients, ¹²³I-MIBG in 31, and CT/MRI in 32. Patient-based sensitivity for ¹⁸F-DOPA PET, ¹²³I-MIBG, and CT/MRI was 90, 65, and 67% (P < 0.01 for ¹⁸F-DOPA PET vs. both ¹²³I-MIBG and CT/MRI, P = 1.0 ¹²³I-MIBG vs. CT/MRI). Lesion-based sensitivities were 73, 48, and 44% (P < 0.001 for ¹⁸F-DOPA PET vs. both ¹²³I-MIBG and CT/MRI, P = 0.51 ¹²³I-MIBG vs. CT/MRI). The combination of ¹⁸F-DOPA PET with CT/MRI was superior to ¹²³I-MIBG with CT/MRI (93 vs. 76%, P < 0.001). Whole-body metabolic burden measured with ¹⁸F-DOPA PET correlated with plasma normetanephrine (r = 0.82), urinary normetanephrine (r = 0.84), and metanephrine (r = 0.57).

Conclusion: To localize tumors causing catecholamine excess, ¹⁸F-DOPA PET is superior to ¹²³I-MIBG scintigraphy and CT/MRI.